McKesson: A Long-Term Owner's Perspective

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it growing a bigger slice of an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: McKesson is almost entirely "growing a bigger slice of an already mature existing pie," not creating an entirely new market. Its ceiling is set by the total usage of U.S. prescription and specialty drugs, not by new demand it opens up on its own—and this is precisely the fundamental reason it does not fit Baillie Gifford's LTGG "entirely new market" narrative.

  First look at the pie itself. McKesson is one of the U.S. pharmaceutical-distribution Big Three, and the report cites Commonwealth Fund data noting that about 92% of U.S. prescription drugs flow through wholesalers, with McKesson, Cencora, and Cardinal Health together accounting for over 90% of U.S. pharmaceutical wholesale. This is a highly concentrated, demand-rigid, structurally stable stock market: the total pool of prescription drugs expands naturally with an aging population, chronic disease, and specialty-drug penetration, not because some disruptive product conjures it into being. McKesson's FY2026 revenue reached $403.4 billion (+12% year over year), of which North American Pharmaceutical alone accounted for about $336.7 billion—this scale itself shows that its growth is "rising with prescription volume and drug prices within an already deeply penetrated distribution pie," not creating a new consumption scenario.

  It does have genuine moves to "thicken the pie," but they still fall within the existing healthcare system, not a new market. McKesson is shifting its profit center from ultra-thin traditional distribution toward Oncology & Multispecialty (FY2026 revenue about $48.4 billion, up +31% year over year), prescription technology services RxTS, and biopharma services. These are higher-quality service-ified businesses—but they serve the same drug companies, pharmacies, hospitals, and oncology clinics, integrating "already-existing healthcare activities" such as community oncology, 3PL, and patient access into its own platform. This is "cutting into the thicker, higher-margin layer within the existing pie," not spawning demand that did not previously exist.

  The ceiling is therefore clear: the upper bound is not high, but it is durable. What Baillie Gifford truly seeks are companies whose TAM is still being stretched by themselves, with a ten-year fivefold imagination wide open; McKesson is not that. Its ceiling is the relatively rigid curve of total U.S. pharmaceutical spending, and management's own long-term targets are candid too—North American Pharmaceutical segment profit growing only 5%–8% long term, and even the fastest, Oncology & Multispecialty, only 13%–16%, with an overall adjusted EPS target of 13%–16%. This is the pace of a high-quality oligopolist "thickening the pie" in a mature market, not the pace of opening up a new continent.

  In a sentence: McKesson's story is "migrating toward the higher-margin thin layer within a mature pie that has a very deep moat but has already been carved up by itself and two rivals." It deserves respect, but measured by Baillie Gifford's yardstick of "creating an entirely new market," this dimension is clearly on the weak side.

  Jun 11, 2026
• QOver the next five years, can its revenue at least double? Is growth driven mainly by volume, price, or new businesses?4/10

  A

  Conclusion: almost impossible. For McKesson to double revenue over the next five years (from $403.4 billion to about $800 billion) requires roughly a 15% compound annual growth rate, far above its actual pace over the past four years and far above management's own guidance. Its growth is driven mainly by "volume" (prescription and specialty-drug usage) and "price" (rising drug prices); what new businesses contribute is profit quality, not revenue scale—so revenue can climb steadily, but doubling is unrealistic.

  First calibrate expectations with history and guidance. The report records McKesson's revenue growing from $263.97 billion in FY2022 to $403.43 billion in FY2026, a four-year compound growth rate of about 11%—already a rather good window (benefiting from rising drug prices and specialty-drug ramp). But 11% revenue growth corresponds to "about 69% growth over five years," still short of doubling; and management cares more about profit than revenue scale, with long-term targets of segment operating profit at 5%–8% (core distribution) to 13%–16% (oncology) and adjusted EPS 13%–16%. Note: these are profit figures; revenue figures are usually slower, because the company is actively shrinking low-quality revenue and growing higher-margin services.

  Breaking down the drivers, their weights are very uneven:

  Volume—the main driver, but low-slope. The absolute bulk of revenue comes from North American Pharmaceutical (about $336.7 billion in FY2026), which grows naturally with prescription volume, new drug launches, and specialty-drug penetration. This is a real but moderate growth source, roughly following the U.S. pharmaceutical-spending curve over the long term, and will not suddenly accelerate to the slope needed to double.

  Price—an important amplifier, but uncontrollable and not its own pricing power. A considerable part of the high revenue growth in recent years came from the "pass-through" amount driven by rising drug prices (especially branded drugs and high-price specialty drugs like GLP-1s). The report makes clear that wholesalers are mostly price takers on branded drugs—meaning the "price" line is decided by drug companies and the market, with McKesson a passive amplifier that could keep boosting it or could reverse due to policy (drug-price reform, PBM restructuring).

  New businesses—drive profit quality, not a revenue doubling. Oncology & Multispecialty revenue was up +31% year over year in FY2026 and RxTS +11%, impressive growth rates, but together (about $48.4 billion + $5.8 billion) they still make up a small share of total revenue. Even if they keep growing at double digits, their pull on a $400-billion-scale total is limited. Their significance is to move the profit pool toward high quality—RxTS adjusted operating margin is as high as about 19.45%, far above core distribution's about 1.03%—not to double revenue.

  One more layer worth spelling out: for McKesson, doubling revenue is not itself a good goal. Its core distribution is an "ultra-thin margin, high-turnover" business, with FY2026 gross margin of only 3.61%; simply growing low-margin distribution revenue creates little value. What truly drives shareholder returns is per-share EPS (FY2026 adjusted $39.11, +18% year over year, FY2027 guidance $43.80–44.60) and continued buybacks, not revenue scale.

  Conclusion on the ground: measured by Baillie Gifford's "five-year revenue doubling" yardstick, McKesson clearly fails—it is a steady compounding machine driven by volume and price and winning through profit-quality migration, not a high-speed growth engine that can double revenue within five years.

  Jun 11, 2026
• QFive years out, what will take the baton as the next growth engine? Does this "second curve" exist today?5/10

  A

  Conclusion: McKesson's "second curve" does exist today and is being delivered—it is the oncology and multispecialty platform (Oncology & Multispecialty) and prescription technology services (RxTS). This is its most solid piece of growth relative to peers. But to be honest: this second curve is "a baton of higher profit quality," not "a brand-new growth pole that could rebuild another McKesson in scale"—it takes the profit baton, not the revenue baton.

  The second curve is not a vision on a slide but a real business already running in the financials. The report and company results confirm that in FY2026 Oncology & Multispecialty revenue was about $48.4 billion, up +31% year over year, with adjusted operating profit up +53%; RxTS revenue was up +11% year over year, with adjusted operating profit up +17%. The key is the generational gap in margins: core distribution (North American Pharmaceutical) adjusted operating margin is only about 1.03%, while RxTS is as high as about 19.45%, Oncology & Multispecialty about 2.96%, and Medical-Surgical about 8.94%. In other words, the profit pool is systematically migrating from "the ultra-thin haulage fee" toward the higher-quality money of "practice management, GPO, patient support, 3PL, technology services." This is a baton pass already happening and verifiable, not a future tense.

  It is supported by real structural trends: consolidation of community oncology platforms, rising specialty-drug penetration, and expansion of biopharma outsourcing services. McKesson is also adding to this curve with M&A—the report records PRISM Vision ($875 million, ophthalmology specialty) and Core Ventures ($2.5 billion in cash, oncology platform), both heading toward higher-margin specialty/services. Management's long-term targets for this curve are also the highest: Oncology & Multispecialty segment profit 13%–16%, RxTS 10%–13%, clearly above core distribution's 5%–8%. This is the affirmative answer to "does the next growth engine exist today."

  But its "scale" must be stated clearly to avoid overstatement. The second curve takes the profit-quality baton, not the revenue-scale baton: Oncology and RxTS combined revenue (about $48.4 billion + $5.8 billion) is still small relative to the $403.4 billion total, and even with sustained double-digit growth it cannot push the company's scale to a new level in the near term. What it can do is "keep McKesson's overall profit growth (EPS target 13%–16%) persistently faster than its low-margin revenue growth," thereby improving business quality—this is an incremental upgrade, not the rebuilding of a growth pole.

  There is also a parallel "value-release" move worth listing separately: the Medical-Surgical Solutions spin-off + Apollo acquiring an approximately 13% convertible preferred equity interest for about $1.25 billion. This is essentially not a "new growth curve" but making the market see more clearly the profit quality of the remaining core business—it belongs to value realization at the capital-structure level, lifting valuation if it holds, but bringing noise during execution.

  From a Baillie Gifford perspective: the fact that McKesson's second curve "exists today and is being delivered" is true and deserves credit; but it is an incremental second curve of "a high-quality oligopolist migrating to a higher-margin layer," not a brand-new growth pole that "opens up a ten-year fivefold imagination." What exists, exists; but do not describe it as something it is not.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: McKesson's core moat is not brand but a systemic capability layered from "scale + national warehouse/distribution network + compliance licenses + customer/supplier relationships"; the report judges that it will "widen slightly overall" over the next three to five years, and I agree with this direction—the traditional distribution moat is stable and the high-margin services moat is widening—but the extent of widening is incremental, not a step change, and the narrow side of the moat (core distribution has almost no pricing power) is also real.

  First, what the moat actually is. This is a business with FY2026 gross margin of only 3.61%, where any company that thrives long term must rely on cost and scale rather than pricing. Its moat is built from several layers: (1) scale purchasing and warehouse/distribution density—the report cites the Commonwealth Fund noting that about 92% of U.S. prescription drugs flow through wholesalers, with McKesson, Cencora, and Cardinal alone holding over 90%, so new entrants cannot replicate this national network and working-capital scale; (2) compliance and licensing barriers—controlled-substance monitoring, quality systems, regulatory scrutiny both squeeze margins and raise the bar for new players; (3) moderate switching costs—pharmacies and hospitals switching their primary wholesaler involves inventory, IT interfaces, payment terms, and service continuity, not a zero-cost move. This is a "real but somewhat narrow" moat: enough to lock the industry into three oligopolists, but not enough to give core distribution strong pricing power.

  Why the "widen" direction over the next three to five years holds—and here one must look at the forward margin, not just historical scale. Historical scale only proves it "was and still is" an oligopolist; what truly decides the moat's trajectory is the speed of profit-structure migration. The evidence is the FY2026 marginal expansion of high-margin services: Oncology & Multispecialty revenue +31%, adjusted operating profit +53%, RxTS revenue +11%. These businesses (practice management, GPO, patient support, 3PL, Ontada data, prescription technology) naturally have higher switching costs and data stickiness—once a customer embeds clinical workflows, data systems, and reimbursement access into the McKesson platform, the cost of leaving is far higher than merely switching a drug hauler. So "the moat widens" not by core distribution getting thicker, but by the profit pool migrating to these stickier service layers. Management's long-term profit targets for these two (13%–16% / 10%–13%) are also higher than core distribution's (5%–8%), consistent in direction.

  But the "could narrow" side must be laid out in parallel, not just the widening: (1) high customer concentration is the flip side of the moat—in FY2026 the top ten customers accounted for about 73% of revenue, with CVS alone about 24%, and large-customer bargaining or vertical integration would directly erode the moat; (2) specialty-drug "limited distribution" and manufacturer direct shipping—the report cites the Commonwealth Fund noting that some high-value specialty drugs are bypassing the traditional wholesale chain, a real erosion of the channel moat; (3) core branded-drug distribution inherently lacks pricing power, and the report rates "pricing power" as a "Fail."

  On the judgment: over the next three to five years, McKesson's moat will most likely "widen slightly overall"—but the widening comes from the slow variable of service-layer profit migration, not from strengthening core distribution; meanwhile the two narrowing pressures of customer concentration and specialty-drug bypass are always present. By Baillie Gifford's yardstick, this is a "real, durable moat widening at the margin, but with a limited ceiling and pricing power," not the same magnitude as a top-tier network moat that "gets wider and takes all."

  Jun 11, 2026
• QIf its core business is disrupted, does it have the genes to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  Conclusion: On "treating mistakes and bad news," McKesson performs maturely and credibly—major negatives like bad debt and opioid litigation it provisions, discloses, and shoulders without concealing; but on "the genes to reinvent itself when the core business is disrupted," its answer is "strong at incremental adaptation, weak at radical self-disruption." It will proactively move its profit center away from sunset segments, but as an asset-heavy, compliance-heavy network company, it lacks the tech-company-style regenerative ability to tear it all down and start over.

  First look at the front half implied in this chained question—"the genes to reinvent itself." McKesson's reinvention is "proactively migrating the profit pool," not "smashing the old model to build a new engine." The evidence is its response to core distribution's long-compressed margin (FY2026 North American Pharmaceutical adjusted operating margin only about 1.03%): rather than clinging to haulage fees, it keeps investing resources in higher-margin oncology/specialty platforms and prescription technology services (Oncology & Multispecialty FY2026 revenue +31%, RxTS +11%), and reshapes its business mix through M&A (PRISM Vision, Core Ventures) and the Medical-Surgical spin-off + Apollo's $1.25 billion stake. This shows it has the organizational ability to "read structural change and proactively adjust formation"—real adaptability.

  But honestly distinguish "adaptability" from "self-reinvention genes." What this Baillie Gifford question really asks is: if the core distribution model is disrupted (say, large-scale limited distribution of specialty drugs, manufacturer direct shipping, PBM/pharmacy ecosystem restructuring marginalizing the traditional wholesale chain), can it reinvent itself like the great growth stocks? McKesson's weakness shows here: it is an asset-heavy oligopolist with a national warehouse/distribution network, enormous working capital, and deep regulatory embedding, and its turning radius is large. The report cites the Commonwealth Fund noting that some specialty drugs are already bypassing the traditional wholesale channel—once this trend accelerates, McKesson's response can only be "embedding itself into the new distribution/service segments," not conjuring a new high-growth species from thin air. Its moat comes from existing infrastructure, which is both an advantage and means it lacks the genes to disrupt itself lightly.

  Now the back half of the question—"how it treats mistakes and bad news," where McKesson passes quite well and deserves credit.

  Bad debt: provision, disclose, get through, no stall. The report records that FY2024 was hit by a Rite Aid-related $725 million bad-debt provision, but the company still generated about $4.31 billion in operating cash flow and about $3.63 billion in free cash flow that year—the bad news was booked truthfully and business resilience did not collapse.

  Opioid litigation: no dodging, no glossing over. In its 10-K the company carries opioid-related estimated liabilities of about $5.7 billion (i.e., $5.7 billion) truthfully, and explicitly states it cannot reasonably estimate the upper and lower bounds of the full ultimate loss—it does not pretend the risk is already zero. The report also notes the latest 10-K lists opioid-related uncertain tax positions as a key audit matter, showing neither the company nor its auditor tried to suppress the complex issue.

  One governance "marginal deterioration" is also worth viewing in contrast. The report notes that from May 1, 2026, CEO Brian Tyler also serves as Chairman; although a Lead Independent Director is in place, this is weaker than a fully independent chair structure—a signal on which I would deduct, but it belongs to "governance preference," not "concealing bad news."

  On the ground: in the dimension of "treating mistakes and bad news," McKesson is honest, mature, and resilient—a trait of high-quality defensive companies; but on what Baillie Gifford truly wants, "the genes to tear it down and rebuild when the core is disrupted," it is on the weak side. It will adapt cleverly; it will not radically reinvent itself.

  Jun 11, 2026
• QAre management (especially the founder) long-term-visioned, with interests deeply tied to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Conclusion: McKesson's management is "professional-manager type, long-term oriented, with shareholder interests broadly aligned," rather than the "founder/controlling-shareholder deeply bound" type Baillie Gifford most favors. The CEO's holdings are high in value (about 29.5 times annual salary) and the incentive design leans long-term; but his personal ownership is less than 1% of the company, and there is no founder soul-figure, so by Baillie Gifford's yardstick this dimension can only be rated upper-middle, not top-tier.

  First answer what Baillie Gifford values most—"binding"—here one must distinguish "percentage" from "amount," and the conclusions differ.

  By absolute ownership percentage, the binding is on the weak side. The report cites the FY2025 Proxy: CEO Brian Tyler's direct beneficial ownership is about 70,828 shares, less than 1% of total shares outstanding (FY2026 diluted shares about 124.1 million). This is not "owner-puts-his-net-worth-in-the-company" controlling management—McKesson is a large-cap blue chip with highly dispersed ownership and no founder/family control, lacking the kind of soul-binding Baillie Gifford most cherishes where "the founder is willing to sacrifice the present for ten years out."

  But by holding value and institutional design, the alignment is quite solid. The report records the company requires the CEO to hold 6 times base salary, and as of March 31, 2025, Tyler's actual holdings were worth about $45.687 million, equal to 29.5 times base salary, far above the threshold; all named executives meet the requirement. The company also prohibits executives from hedging/pledging, uses double-trigger change-of-control provisions, and has a clawback mechanism. These are all "long-term-leaning, shareholder-oriented" healthy designs—management may not be a major shareholder, but the incentive structure ties their wealth to the long-term share price.

  Now on "whether they are willing to sacrifice current profit for five to ten years out"—here McKesson's behavioral evidence is actually positive. It has not clung to its largest current revenue source (ultra-thin-margin core distribution), but has proactively directed resources and capital toward businesses with small near-term revenue contribution but better long-term profit quality: Oncology & Multispecialty (FY2026 revenue +31%), RxTS, and it proactively simplifies its mix and realizes value through the Medical-Surgical spin-off + Apollo's $1.25 billion stake. Management raised the long-term EPS target to 13%–16% at Investor Day and explicitly bets the future on a better mix of "distribution + specialty + technology + services" rather than low-margin scale expansion—a restrained rather than short-sighted capital-allocation stance.

  On capital-allocation discipline there is one reservation: buybacks are aggressive but increasingly expensive. The report records the company repurchasing at average prices of about $436, $543, and $754 in FY2024–FY2026, with the FY2026 average already very high—showing management is aggressive in "returning cash to shareholders" but not strict about "buying back heavily only when clearly undervalued." This does not harm shareholders, but it is not Buffett-style contrarian buyback discipline.

  There is also one governance deduction to list truthfully: from May 1, 2026, Brian Tyler also serves as Chairman, and although a Lead Independent Director is in place at the same time, it is weaker than a fully independent chair structure—for a company of this size, regulatory sensitivity, and M&A activity, separating CEO and Chair should be more prudent.

  On the ground: by Baillie Gifford's "founder-style long-term binding" yardstick, McKesson is "an excellent professional-management team, healthy incentives, long-term behavior," but lacks the strongest binding layer of a founder's soul and high-percentage control. It is trustworthy, trackable management, but not the ideal type in the Baillie Gifford lineage that is "deeply consubstantial with the company's fate." The report gives 4/5, and I agree.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not reliant on harming society and regulation?5/10

  A

  Conclusion: If McKesson disappeared tomorrow, the U.S. healthcare system would feel "immediate acute pain"—it is one of the key infrastructures moving prescription drugs from drug companies to pharmacies/hospitals/clinics, with extremely high short-term irreplaceability. But honestly answer this question's dual implicit premise: its "indispensability" is strong, while the "social and regulatory sustainability" of its growth model carries a real tail flaw—opioid litigation. The two must be viewed side by side.

  First look at "indispensability"—McKesson's hardest side. The report cites the Commonwealth Fund noting that about 92% of U.S. prescription drugs flow through wholesalers, with McKesson, Cencora, and Cardinal together holding over 90%. McKesson's FY2026 revenue of $403.4 billion serves chain pharmacies, independent pharmacies, hospitals, oncology and specialty clinics, and government agencies—it carries large-scale, compliant, traceable drug distribution and inventory turnover. Such a national warehouse/distribution network cannot be replaced by anyone in the short term: if it truly disappeared, the drug-supply chain for chronic-disease, oncology, and specialty-drug patients would break, and hospitals and pharmacies would immediately fall into drug shortages and fulfillment crises. From the angle of "how much customers would miss it," the answer is "miss it extremely, with no short-term substitute."

  But one layer must be spelled out to avoid misreading "indispensable" as "winner-take-all dominance." McKesson's indispensability is "in the sense of systemic infrastructure," not "in the sense of charging whatever I want." The report is clear: core branded-drug distribution lacks pricing power (pricing power rated "Fail"), and it is mostly a price taker on branded drugs. That is, it is indispensable yet not dominant—customers cannot do without it, but customers (especially CVS, about 24% of revenue, top ten 73%) have equally strong bargaining power. This is an indispensability of "mutual dependence, but the profit-allocation power is not in its hands."

  Now the most crucial and most easily dodged back half of the question—whether the growth model is socially/regulatorily sustainable. Here there is a real flaw that must be stated plainly:

  Opioid litigation is a stain of social cost on McKesson's growth history that cannot be washed away. The company's 10-K carries opioid-related estimated liabilities of about $5.7 billion (i.e., $5.7 billion), and explicitly states it cannot reasonably estimate the upper and lower bounds of the full ultimate loss. This means part of its past distribution business was found to be related to the opioid-abuse crisis—empirical evidence of "a growth model harming society and already turned into ongoing legal cash flows," a real deduction on this question that cannot be waved away with "the whole industry is like this." The report is right to list it as one of the most core risks.

  Regulatory sustainability is on the whole "heavily pressured but compliant." Pharmaceutical distribution is a highly regulated industry—controlled-substance monitoring, quality systems, regulatory scrutiny. The report notes this both suppresses margins and raises the bar for new entrants. McKesson operates within the regulatory framework, and its compliance system is itself part of its moat; apart from the historical opioid tail, its core business is not the type that "profits from regulatory arbitrage or harming public health"—it is a load-bearing wall for the normal functioning of the healthcare system.

  On the ground: by Baillie Gifford's dual yardstick of "how much the world would miss it if it disappeared + whether growth is clean and sustainable"—McKesson scores high on "indispensability" (infrastructure-grade, no short-term substitute), but is dragged on "social/regulatory cleanliness" by the opioid-litigation tail flaw. It is a company society truly needs, yet carrying an unsettled historical moral/legal debt. The honest conclusion: indispensability is true, but "clean, flawless, sustainable growth" is discounted.

  Jun 11, 2026
• QWhat are this business's unit economics (gross margin, incremental returns)? Does it get better or worse at greater scale? Where does the money it earns go?5/10

  A

  Conclusion: McKesson's unit economics are a special combination of "ultra-thin margin but extremely high incremental return"—reported gross margin of only about 3.61%, turned by enormous scale, working-capital float, and extremely low incremental capital investment into a powerful cash machine; growing bigger makes it "better" (cost spreading, upward mix shift), not worse. The money it earns goes mainly to buybacks, dividends, and M&A into high-margin specialty/services. By Baillie Gifford's yardstick this dimension is actually a relative strength.

  First look at gross margin—ugly on the surface, but understand why it does not matter. The report records McKesson's FY2026 gross margin of only 3.61%, FY2025 3.71%, and a downward trend (FY2022 was still 4.97%). But this is the nature of the drug-distribution business, not a signal of deterioration: it is an "ultra-thin margin, high-turnover, operations-heavy" channel business, relying not on pricing but on turnover and scale. More crucially, the profit structure is diverging—core distribution adjusted operating margin is only about 1.03%, while RxTS is as high as about 19.45%, Medical-Surgical about 8.94%, and Oncology & Multispecialty about 2.96%. So "reported gross margin diluted" and "underlying profit quality improving" happen at the same time: the surface of the statements is not so pretty, but the mix is actually optimizing.

  What truly defines this business are two hidden engines:

  First, incremental return on capital is extremely excellent—a point Baillie Gifford would value. The report notes: FY2026 operating cash flow $6.155 billion, while PP&E spending was only $436 million and capitalized software $309 million, together about $745 million. That is, to generate hundreds of billions of dollars in revenue, the annual tangible/capitalizable investment it needs is extremely low—growth barely consumes capital. Note: metrics like ROE/ROIC are severely distorted for it (the company has about -$2.172 billion shareholders' equity deficit from long-term large buybacks, so P/B and ROE cannot be used mechanically), but from the "incremental return on capital" angle, this is a very efficient business. In the report's investment checklist, "is return on capital excellent" is answered "ROE/P/B distorted, but incremental return on capital excellent."

  Second, working-capital float is its cash engine. The report breaks down the FY2026 operating-cash-flow composition: receivables up $1.999 billion, inventory up $1.082 billion, but payables up $4.317 billion—the net effect is that working capital contributes positive momentum to cash flow. This is the core economic feature of large distributors: not high margin, but "manufacturing cash" through credit, scale, and turnover. The result is cash profit significantly stronger than accounting profit—FY2023–FY2026 free cash flow / net income to parent is about 1.31x. But the report also adds a conservative caveat I agree with: this float is not all distributable painlessly every year and should not be treated as pure excess cash.

  Better or worse at greater scale? Clearly better. In an industry with 3%–4% gross margins, scale is not "optional" but the business model itself—purchasing negotiations, distribution density, compliance systems, IT investment, and working-capital efficiency all rely on scale to spread costs. McKesson, Cencora, and Cardinal locking the market into an oligopoly is precisely evidence that the unit-cost advantage from scale cannot be replicated by new entrants. The larger the scale, the lower the unit cost and the more the mix can shift toward high-margin services—so its unit economics improve with scale, not diminish.

  Where does the money it earns go? Three destinations, with generally good discipline. (1) Buybacks—the report records FY2024–FY2026 buybacks of about $3 billion, $3.1 billion, and $4.75 billion, with FY2026 adding a $5 billion authorization (total authorization to $7.7 billion); FY2022–FY2026 diluted shares fell from 154.1 million to 124.1 million, a nearly 19.5% reduction over four years, meaningfully accreting per-share value. (2) Dividends—dividend per share rose steadily from $1.83 in FY2022 to $3.17 in FY2026. (3) M&A—toward higher-margin specialty/ophthalmology/oncology platforms (PRISM Vision $875 million, Core Ventures $2.5 billion). The only reservation is that the average buyback price keeps rising (about $754 in FY2026), right direction, mediocre price discipline.

  On the ground: on this unit-economics question, McKesson is actually one of the dimensions it can most stand on—beneath the thin-margin shell is a genuinely high-quality business with high incremental returns, strong cash conversion, and improvement with scale, and the money it earns goes mainly to accreting per-share value. This is the core basis for it deserving a spot on the "high-quality watch list."

  Jun 11, 2026
• QFor it to rise fivefold in ten years, what conditions must hold simultaneously? Are these conditions realistic? What expectations does today's share price imply?2/10

  A

  Conclusion: For McKesson to rise fivefold in ten years (from about $777 to about $3,850) requires about a 17.5% annualized total return, which needs "EPS delivering at the 13%–16% upper bound for ten straight years + valuation multiple not contracting or even expanding + all three risks (opioid/customer concentration/spin-off) staying unblown" to hold simultaneously. Each of these alone is not absurd, but stacked together they are very demanding. And today's stock at about 22x P/E actually implies "quality improvement is substantially priced in, margin of safety not obvious"—it implies fair-to-optimistic, not undervalued. So fivefold is a low-probability event, by no means the base case.

  First lay out the math. The current share price is about $776.95, market cap about $93.4 billion. Fivefold in ten years means about 17.5% annualized price return. McKesson's return comes from three parts: EPS growth + dividend (FY2026 $3.17 per share, yield about 0.4%, nearly negligible) + valuation-multiple change. The dividend contribution is tiny, so fivefold rests almost entirely on "EPS compound growth × valuation multiple."

  For fivefold to hold, the following conditions must be met simultaneously:

  (1) EPS must run at the upper bound of the long-term target for ten straight years. Management's long-term adjusted EPS target is 13%–16%. Compounding at the 16% upper bound for ten years gives EPS about 4.4x; to reach a 5x share price, the valuation multiple must also expand slightly. At the 13% midpoint, EPS is about 3.4x, requiring a clear valuation expansion to suffice—and it is already at about 22x P/E, with limited expansion room. In other words, fivefold requires "persistently outrunning its own raised target upper bound," a high bar in itself.

  (2) The high-margin engines must keep delivering above target. That is, Oncology & Multispecialty (target profit growth 13%–16%) and RxTS (10%–13%) do not lose speed long term, M&A (PRISM Vision, Core Ventures) integration returns are realized, and the overall profit structure keeps being pulled up. FY2026 they did run well (Oncology revenue +31%), but sustaining it for ten years is another matter.

  (3) The valuation multiple must not contract, ideally even expand. This is at odds with reality—it is already not cheap (see below). Once the market compresses a high-quality distributor from about 22x P/E back to 17–18x (a real risk the report notes), EPS growth would be eaten by valuation contraction, and fivefold would be off the table.

  (4) The three tail risks stay unblown for ten years. Opioid liabilities (about $5.7 billion, ultimate unclear) are not significantly revised up; the CVS about 24% of revenue, top-ten 73% customer concentration does not trigger a profit re-pricing; the Medical-Surgical spin-off and M&A have no execution accidents. If any one blows up, fivefold is directly out.

  What does today's share price imply?—it implies "quality improvement already paid for, fair-to-optimistic," not undervalued. The report's conservative Owner Earnings estimate is about $5 billion, corresponding to about 19x conservative Owner Earnings, a free-cash-flow yield of about 5.3%, while the U.S. 10-year Treasury is about 4.57%—excess compensation of only about 0.7 percentage points, a margin of safety that is "not obvious." On relative valuation, McKesson's about 22x P/E versus Cencora's about 20x is no meaningful discount. That is, the market has already paid for its cash-flow quality and defensiveness—the current price implies "the company continues to deliver steadily on the 13%–16% EPS target," a rather positive expectation, not "the market is bearish and leaves ample margin of safety." This is also confirmed by the sell-side consensus: 17 analysts with an average target price of about $966 and a rating leaning "Strong Buy"—the consensus is already on the optimistic side, hardly with expectations undervalued.

  On the ground: by Baillie Gifford's "what conditions must hold simultaneously for a ten-year fivefold" yardstick, McKesson requires the low-probability conjunction of "EPS running the full upper bound + valuation not contracting + all three risks unblown," while the current price gives no discount cushion—the conclusion is that fivefold is low-probability, not the base case. Its more reasonable long-term positioning is a compounding name of "mid-to-high single digits, reaching low double digits when things go well" (the report's expected annualized: conservative 4%–6%, neutral 8%–11%, optimistic 12%–14%), not a ten-year-fivefold candidate in the Baillie Gifford sense.

  Jun 11, 2026
• QWhy hasn't the market realized all this yet? Is it that it cannot understand, looks down on it, or cannot see far enough? What would become the "narrative inflection point"?3/10

  A

  Conclusion: For McKesson, the question "why hasn't the market realized" does not stand—the market realized long ago. It is a large-cap blue chip covered deeply by 17-plus sell-side houses, rated leaning "Strong Buy," and already not cheap; there is no perception gap of "cannot understand, looks down on, cannot see far." Its recent pullback from about $994 to about $777 is not the market "failing to discover value," but the market "re-pricing the known over-valuation + customer concentration/opioid/policy risk." So the honest answer to this Baillie Gifford question is: there is no buried perception gap, and therefore no clear positive "narrative inflection point" to wait for.

  First answer the "cannot understand/looks down on/cannot see far" trio head-on—none of the three holds:

  Not "cannot understand." McKesson is an S&P 500 constituent with detailed disclosure and a clear business model (the report itself rates its understandability 4/5). Sell-side coverage is dense, with 17 analysts at an average target price of about $966, and JPM, Barclays, and others continuously updating models—this is a stock researched inside out, not an obscure name nobody understands.

  Not "looks down on." On the contrary, the market gives it a not-low mark. The report estimates it at about 22x P/E, a conservative Owner Earnings yield of about 5.3%, an excess compensation over the 10-year Treasury (about 4.57%) of only about 0.7 percentage points; versus Cencora's about 20x P/E there is also no meaningful discount. The market has already paid a premium for its cash-flow quality and defensiveness—this is "respected, even fully priced," not slighted.

  Not "cannot see far." Its second curve (Oncology & Multispecialty, RxTS) and long-term EPS target 13%–16% are public and repeatedly discussed; the FY2027 EPS guidance $43.80–44.60 is already priced in by the sell side. The market sees far; the disagreement is only over "how many times to pay," not "cannot see the future."

  Then why did it fall recently?—this precisely proves the market is actively pricing, not ignoring. Its fall from the all-time high of about $994 in March 2026 to about $777 (touching a 52-week low of about $637 at one point) is the market re-pricing several known things: an already-high valuation, customer concentration such as CVS, the opioid-liability tail, drug-price/PBM policy uncertainty, and the execution noise of the Medical-Surgical spin-off and M&A. This is "re-pricing of known risk," not "undiscovered value"—the opposite direction from the "undervalued good company the market has not yet realized" that Baillie Gifford seeks.

  Then what would the "narrative inflection point" be?—distinguish positive from negative, and the odds on the positive inflection are not enticing. What this Baillie Gifford question seeks is a positive inflection that "suddenly makes the market re-rate and opens upside." For McKesson, possible positive catalysts are: (1) the Medical-Surgical spin-off + Apollo's $1.25 billion stake completing smoothly, letting the market see more clearly the high profit quality of the remaining core business and granting a higher multiple; (2) the high-margin engines keeping delivering above target, forcing the market to revise up its long-term growth assumption; (3) the opioid-liability shoe dropping with an ultimate loss below fears. But honestly: these are all "already known to the market, awaiting results," not hidden perception gaps—their realization only lets the valuation return from "fair-to-expensive" to "fair," with upside capped by the current price. Conversely, if a negative inflection (high-margin businesses losing speed, a large-customer contract deteriorating, opioid revised significantly up, a spin-off accident, valuation compressed from 22x back to 17–18x) occurs, the damage is more direct, and the report lists the latter as the "most realistic risk."

  On the ground: by Baillie Gifford's "why hasn't the market realized + what would become the narrative inflection point" yardstick—McKesson's honest answer is "the market realized long ago and has fully priced it," with no perception gap to profit from; it has no clear positive narrative inflection to wait for, and is instead a name where "a good company, but the price has priced in the goodness, and the risks are being re-priced." This fully aligns with the report's conclusion of "Watch, margin of safety not obvious": it is not a story waiting to be discovered by the market, but a story waiting for a better price.

  Jun 11, 2026